Vote Delayed as Republicans Struggle to Marshal Support for Health Care Bill – New York Times

Its hard to see how tinkering is going to satisfy my personal concerns, Ms. Collins told reporters.

A real-time count of every senators position.

Negotiations on Tuesday that leaders hoped would move senators toward yes only exposed the fissures in the Republican Party. Conservatives were demanding that states be allowed to waive the Affordable Care Acts prohibition on insurance companies charging sick people more for coverage and are asking for a more expansive waiver system for state regulators. They also wanted more money for tax-free health savings accounts to help people pay for private insurance.

Senators from states that expanded the Medicaid program and Senator Susan Collins, Republican of Maine would not brook many of those changes, especially the measure to severely undermine protections for people with pre-existing medical conditions. They wanted more money for mental health benefits for people addicted to opioids and money for states to cover people left behind by the rollback of the Medicaid program in both the House and Senate versions.

Three Republican senators Ms. Collins, Rand Paul of Kentucky and Ron Johnson of Wisconsin had announced they would vote against the motion to begin debate that had been scheduled to hit the Senate floor on Wednesday, joining Senator Dean Heller of Nevada, who made the same pledge on Friday.

A bevy of other senators from both flanks of the party seemed headed in the same direction if they did not see changes made to the Senate health care bill, leaving the measure in deep peril, since Republicans can only lose two votes from their own party.

The release of a Congressional Budget Office evaluation on Monday did little to help leaders roll up votes from either side of the fence. The budget office said the Senate bill would leave 22 million more uninsured after 10 years, while sending out-of-pocket medical expenses skyrocketing for the working poor and those nearing retirement.

The budget office did not provide conservatives with support for their demands either. The state waivers already in the Senate bill would probably cause market instability in some areas and would have little effect on the number of people insured by 2026, the analysis concluded. Adding still more waivers, including one that could allow insurers to price the sick out of the health care market, could deprive even more people of health care.

Even before Mr. McConnells decision, White House officials had braced for the likelihood that the procedural vote would fail and that they would have to revisit the measure after the Fourth of July recess when they hoped to be able to woo Mr. Johnson, who has been a surprisingly fierce critic of the bill from the right. The senator has repeatedly warned that this week is too soon to vote on the health care measure, as Republican senate leaders have insisted they need to do.

Vice President Mike Pence, attended the Senate Republican lunch on Tuesday and then broke off for private meetings with Mr. Heller, a seemingly firm no and the first moderate Republican to break with Mr. McConnell over the bill, and Rob Portman of Ohio, who is feeling pressure from his states governor, John R. Kasich, to oppose the bill and defend Ohios Medicaid expansion.

Mr. Portman was the subject of a spirited evaluation of his open criticism of the bill by Mr. McConnell, who was frustrated with the expansion-state senators who showed their hand early to other wavering colleagues, dooming the bill for now. Mr. McConnell was unhappy that Mr. Portman seemed to be abandoning his previous stance on fiscal rectitude by opposing Medicaid cuts in the bill.

But the Ohio senator was getting it from both sides. Mr. Kasich appeared in Washington on Tuesday to sharply criticize the Senate bill. The governor said he was deeply concerned about millions of people losing coverage under the bill.

Who would lose this coverage? Mr. Kasich said. The mentally ill, the drug addicted, the chronically ill. I believe these are people that need to have coverage.

At the same news conference, Colorados Democratic governor, John W. Hickenlooper, said his states Republican senator, Cory Gardner, understands the hardships and the difficulties in rural life.

This bill would punish people in rural Colorado, Mr. Hickenlooper said, raising the pressure.

Doctors, hospitals and other health care provider groups came out strongly against the Senate bill, as did patient advocacy groups like the American Heart Association. But business groups were ramping up their support. In a letter on Tuesday, the U.S. Chamber of Commerce endorsed the Senate bill and urged senators to vote for it.

The Senate bill will repeal the most egregious taxes and mandates of the Affordable Care Act, allowing employers to create more jobs, said Jack Howard, a senior vice president of the group. The bill, he noted, would repeal a tax on medical devices and eliminate penalties on large employers that do not offer coverage to employees.

A separate letter expressing general support for the Senates efforts was sent by a coalition of 28 business and employer groups including the National Association of Home Builders, the National Restaurant Association and the National Retail Federation.

But Senate conservatives found themselves squeezed between business sentiment and their conservative base. Club for Growth, an ardently conservative political action committee, came out strongly against the Senate measure on Tuesday.

The Club for Growth and the American people took Republicans in Congress at their word when they promised to repeal every word root and branch of Obamacare and replace it with a patient-centered approach to health care, the groups president, David McIntosh, said in a statement. Only in Washington does repeal translate to restore. Because thats exactly what the Senate GOP healthcare bill does: it restores Obamacare.

Even the Trump administration is divided over what comes next, especially on the payment of subsidies to health insurance companies to compensate for reducing out-of-pocket costs for low-income people.

Mr. Trump has threatened to withhold the monthly payments as a way to induce Democrats to bargain with him over the future of the Affordable Care Act. Administration officials said Mr. Trump did not want to make the payments if the Senate did not pass a health care bill this week. But they said Tom Price, the secretary of health and human services, had urged the White House not to cut off the payments abruptly.

A federal judge has ruled that the payments are illegal because Congress never appropriated money for them, but that ruling is being appealed. Any interruption of the payments could have a dire destabilizing effect on markets, insurers say. Blue Cross Blue Shield of North Carolina recently blamed the Trump administrations mixed signals on the subsidy for most of its proposed 23 percent spike in premiums next year.

Sean Spicer, the White House press secretary, defended the administrations position at his briefing on Friday.

If the president were to hypothetically say that hes going to make the payments in perpetuity or for a year, I think that continues to prop up a failed system, Mr. Spicer said. It continues to do wrong by the American taxpayer. And it also doesnt lend itself to the expediency that I think we want to help get a new health care system in place.

Originally posted here:

Vote Delayed as Republicans Struggle to Marshal Support for Health Care Bill - New York Times

A mother’s response to the health-care debate: Her 3-year-old son’s $231000 hospital bill – Washington Post

Alison Chandra's unborn son faced daunting odds of making it to his first birthday. And keeping him alive meant risky, expensive surgeries that their small family couldn't afford.Still, Chandra admits, she felt a bit of shame as she walked into the welfare office.

I remember sitting across the desk from the woman in the office, Chandra told The Washington Post. She said its going to be okay. And I just I think I hugged her. It was the first time that someone was able to tell me that something in this whole nightmare was going to be okay.

There was a safety net and I was falling into it.

At a prenatal sonogram, Chandra and her husband learned that they were having a boy, and that he had a rare disorder called heterotaxy syndrome.

He was born with nine heart defects, two left lungs and five spleens of dubious function, Chandra said. His liver and gallbladder are down the middle of his body, along with his heart, which needs a pacemaker to pump.

[No, the government did not pay for Mitch McConnells polio care. Charity did.]

Ethan's thirdbirthday is Saturday, but he's been through four open-chest surgeries. They've cost millions, Chandra estimates, and almost all of his early care was paid for by Obamacare.

Even though the family is no longer relying on Obamacare, his mother says her son is the poster child for Obamacare. And she's using hisstory as a message to Republicans attempting to change the health-care law.

Senate Republican leaders are trying to overhaul the 2010 Affordable Care Act and pass a new health-care bill, though they are facing opposition from the conservative andmoderate wings of the party. Senate leaders announced on Tuesday that they'd postponed a vote on the legislation until after the July 4 recess.

Senate Majority Leader Mitch McConnell (R-Ky.) unveiled the legislation that would reshape a big piece of the U.S. health-care system on Thursday, June 22. Here's what we know about the bill. (Monica Akhtar/The Washington Post)

The Congressional Budget Office forecasts that the billwould cause about 22 millionmore Americans to be uninsured in the next decade. That number is just over a million fewer than the CBO estimate on the House version of the bill, which was passed hastily last month.

As the debate rages, the picture Chandratweeted of her son's adorable face, surgery scar and protruding pacemaker has rocketed around the Internet, along with its potent message:

Look my son in the eyes and tell him that he's fought so hard to be here but sorry, you're just not worth it anymore, she tweeted. I dare you.

And on Friday, she posted another image: Her son's $231,000 hospital bill from his recent heart surgery.

She's transparent in what she's trying to do: Put a cuddly human face on a debate about health care that she believes is filled with cost-benefit analyses and shouting.

She hopes their story helps people on both sides of the debate just quiet down a little bit and look at each other. Come over to my house and spend the day with us and just look at my kid. Hes more than just a hospital bill. He's more than his preexisting condition.

Obamacare isn't perfect, she concedes, but it's given her nearly three years with her son, who has developed an intense obsession with animals and is looking forward to a moose-themed birthday party Saturday.

Accepting government health care was a tough, embarrassing choice at first, she told The Washington Post, but it was the best way for her tofight for Ethan.

Chandra is a registered pediatric nurse and she and her husband were volunteers for Mercy Ships, a nonprofit that docks floating medical centers at needy countries, offering free specialized surgery and other medical care. She understands that health care is about healing, yes, but also involves triage and prioritizing needs in a world where health care costs money and resources are finite.

They had insurance when they got pregnant with Ethan, but it maxed out during the litany of prenatal tests.

We came home expecting to have our baby and go right back to the ship, she said. Suddenly we were facing this incredibly uncertain future for our kid.

Obamacare was a stopgap measure until her husband, an engineer, found a job with health benefits.

Ethan didn't ask to be born with a preexisting condition, Chandra said. It's hard to preach personal responsibility to a 2-year-old.

Obamacare was a way that our country provided for us to be able to fight for our kid.

Now, their family is fighting against attempts to get rid of some of the provisions that helped save Ethan's life.

[An emotional Jimmy Kimmel discusses newborn sons heart disease, makes passionate health-care plea]

A Republican-backed health-care bill has passed the House and senators are working to modify their overhaul to make it more palatable. But critics have said the bill would mean millions of people like Ethan, who have preexisting conditions, could lose coverage.

Chandra said she's also wary of language that would allow insurers to impose lifetime or annual caps, which could directly hurt her son, even though they've now switched to her husband's employer's health plan.

I don't think anyone can look a 2-year-old child in the face and say 'I think that you're not worth it,' " she said. What they're doing with a lifetime cap is saying you have used up enough resources. I'm sorry that you were born sick. I'm sorry that your mother chose life for you, but now that life is not worth saving anymore.

There is no cure for heterotaxy. Ethan will probably always bedependent on his pacemaker, for example. In the meantime, she says, she's doing everything in her power to help her son thrive, while poring over any medical advancement that could give them more time with Ethan.

She already considers herself among the lucky ones. Between his major surgeries, he's an active almost 3-year-old who makes mud pies and runs through the woods with his older sister.

And along the way, she's seen small victories in a battle she hopes lasts for decades.

Theres actually a specific moment when he realized that his life has changed, she said. He was walking with me. It was shortly after the surgery in February. He would stop every few steps and tell me 'I have to rest now.'

But he kind of stopped, he looked at me and he said, 'Mama, Im not really tired. Im not getting tired.'

And he said, 'Mama, Im Superman.' And he just took off running. He ran like a quarter-mile before he stopped.

Kristine Phillips contributed to this report.

Read more:

A 7-year-old told her bus driver she couldnt wake her parents. Police found them dead at home.

She loved the river. A brain-eating amoeba lurking in the water ended up killing her.

A 4-year-old dies days after going swimming. Was dry drowning to blame?

A teen chugged a latte, a Mountain Dew and an energy drink. The caffeine binge led to his death.

Read the rest here:

A mother's response to the health-care debate: Her 3-year-old son's $231000 hospital bill - Washington Post

As Trump’s Tactics Fall Short, Pence Takes Lead on Health Care Bill – New York Times

Josh Holmes, Mr. McConnells former chief of staff, said, That the White House is asking people to take a tough vote and then running ads against members while were still in negotiations is so dumb its amazing we even have to have the conversation.

Mr. Priebus did not respond to numerous messages seeking comment.

A broad range of Republican senators across the ideological spectrum have indicated their unease with the compromise health bill, which was largely drafted in secret over the last month. But Mr. Trump has few ties with the group, and several Republicans who remain on the fence have tangled with Mr. Trump, either during the presidential campaign or since. As a result, the Republican Senate leadership has made it known that they would much rather negotiate with Mr. Pence than the president himself, according to several White House and congressional officials.

Mr. Trump jumped in only when it became clear Republican leaders were postponing the vote until after the recess, announcing Tuesday afternoon that he was summoning all 52 Republican senators to the White House for some last-ditch diplomacy later in the day.

Top Trump lieutenants like Stephen K. Bannon, his chief strategist, who lobbied members on the House bill, have been all but sidelined. Mr. Priebus has also played a much diminished role.

While Mr. Trump has spoken with several members of the Senate, he has no plans to visit the Capitol, according to an administration official. He spoke with Senator Ted Cruz of Texas, his main rival for the 2016 nomination, over the weekend, as well as Senator Mike Lee of Utah and one or two others, but the pace was nothing like the dozens of calls he made to help pass the Houses health bill, aides said.

Mr. Pence was scheduled to attend the weekly lunch held by the Senate Republicans on Tuesday and planned to engage in conversations with undecided Republicans like Senator Rob Portman of Ohio. The vice president is likely to add other senators to his must-see list, and he plans to host a health-care-related dinner at his house Tuesday night, with Mr. Lee and Senators Tom Cotton of Arkansas, Ben Sasse of Nebraska and James Lankford of Oklahoma, according to a senior administration official. Mr. Sasse has been an understated but strong opponent of the bill as written.

Seema Verma, Mr. Pences former adviser in the Indiana statehouse and now a top administration health care official, has been trying to reassure senators that their states will have flexibility on Medicaid under the bill while Mr. Pences former chief of staff, Marc Short, now the White House legislative affairs director, has been quarterbacking the effort from his hideaway in the Capitol.

Mr. Heller, the only Senate Republican who will face voters next year in a state carried by Hillary Clinton in 2016, is the top target for Democrats facing a Senate map with few opportunities in 2018. And there were already seven groups a mix of health care advocacy organizations and more partisan Democratic efforts on the air in Nevada assailing the Republican health care overhaul, according to a Republican ad buyer tracking the ad traffic.

That an ostensibly pro-Republican group would respond to Mr. Hellers criticism of the legislation he flayed the proposal in harsh terms on Friday but did not rule out eventually backing it by swiftly accusing him of siding with Nancy Pelosi was a shock to Mr. McConnell, who has made no secret of his impatience with Mr. Trumps impulsive style.

It is also caught him off-guard. Neither Mr. McConnells office nor his top outside political advisers were warned about an impending attack on one of their most endangered incumbents. They didnt check in with anybody, Mr. Holmes said. There was no clearing of channels, no heads up, nothing.

The anti-Heller assault began with a digital buy over the weekend, but it was unclear whether the pro-Trump group would follow through with its threat to spend over $1 million attacking the senator. As of Tuesday, the group had reserved just over $250,000 for ads in Las Vegas and Reno, the two largest media markets in the state, according to the ad buyer.

The move against Mr. Heller had the blessing of the White House, according to an official with America First. Mr. Trumps allies were furious that the senator would join Gov. Brian Sandoval, who accepted the Medicaid expansion under the health law and opposes the Republican overhaul, to blast the bill.

But the frustration on Capitol Hill with Mr. Trump and his allies runs far deeper than the ads aimed at the Nevada senator.

While Mr. Trump has taken to Twitter and made phone calls in an effort to lobby his party to pass the health overhaul, he has also provided Democrats with potential weapons, namely his description of the House bill he worked to pass as mean.

See the rest here:

As Trump's Tactics Fall Short, Pence Takes Lead on Health Care Bill - New York Times

Pence to join Senate Republican leaders in healthcare push – Reuters

WASHINGTON Facing a potentially disastrous defeat by members of his own party, U.S. Senate Majority Leader Mitch McConnell decided on Tuesday to delay a vote on healthcare legislation in order to get more support from Republican senators.

President Donald Trump summoned all 52 Republican senators to the White House on Tuesday afternoon to discuss how to proceed.

McConnell had been pushing for a vote ahead of the July 4 recess that starts at the end of the week. The legislation would advance a repeal of major elements of Obamacare and replace it with a new federal healthcare program.

The delay showed McConnell and Trump have failed so far to attract enough votes amid a solid block of Democratic opposition and attacks from both moderate and conservative Republican senators.

McConnell, who has a razor-thin majority in the Senate, told reporters that Republican leaders were still working to get the 50 votes to pass the bill, adding that the White House was anxious to help write legislation that could pass the Senate.

While the House of Representatives narrowly passed a measure last month to replace Obamacare, the Senate version stalled on Tuesday as a small but potentially crippling group of senators held out.

Moderate senators worried that millions of people would lose their insurance. Conservatives said the bill does not do enough to erase Democratic former President Barack Obama's signature domestic legislation.

U.S. stock prices fell on Tuesday after the decision to postpone the vote. U.S. stocks have rallied this year on hopes for tax reform, deregulation and changes to the health sector. Markets are beginning to doubt whether the Trump administration can fulfill its promises.

By early afternoon the benchmark S&P 500 index was down 0.5 percent and the Dow Jones industrial average was off 0.2 percent.

The market likes certainty and now theres uncertainty. What is this going to look like when this gets out of the next iteration?," said Peter Costa, president of trading firm Empire Executions Inc.

The bill's prospects were not helped by an analysis by the nonpartisan Congressional Budget Office on Monday saying the measure would cause 22 million Americans to lose medical insurance over the next decade even as it reduced the federal deficit by $321 billion over the next decade.

The report prompted Senator Susan Collins, a key moderate vote, to say she could not support moving forward on the bill as it stands.

At least four conservative Republican senators said they were still opposed after the CBO analysis.

Passing the measure would hand Trump a legislative win as he seeks to shift attention after weeks of questions over Russia's role in last year's U.S. presidential election.

'ROOT AND BRANCH'

McConnell has promised since 2010 that Republicans, who view Obamacare as a costly government intrusion, would destroy the law "root and branch" if they controlled Congress and the White House. Their electoral victories in 2014 and 2016 were directly tied to that promise, they say.

Republicans worry that failure to deliver will tell voters that they are unable to govern effectively in the run-up to next year's congressional elections.

If the Senate passes a bill, it will either have to be approved by the House, which passed its own version last month, or the two chambers would reconcile their differences in a conference committee. Otherwise, the House could pass a new version and bounce it back to the Senate.

Democrats remained united in opposition, blasting the Senate bill as a tax break for the wealthy.

(Additional reporting by Yasmeen Abulateb, Amanda Becker, Eric Walsh, Susan Heavey and Tim Ahmann; Writing by Richard Cowan and Frances Kerry; Editing by Jeffrey Benkoe)

COLORADO SPRINGS, Colo. At a glitzy weekend gathering of donors to the powerful Koch brothers' network, much of the talk was about the conservative political group's criticism of the healthcare bill moving through the U.S. Senate.

Irish Prime Minister Leo Varadkar held a phone call with U.S. President Donald Trump in which he discussed migration and Britain's exit from the European Union, the Irish government said in a statement on Tuesday.

See the original post here:

Pence to join Senate Republican leaders in healthcare push - Reuters

Jeffrey Sachs: America can save $1 trillion and get better health care – CNN

Of the two options, Obamacare is vastly more just. The Republican plan is ghastly. But America has a much better choice: health for all at far lower costs.

This might seem like an out-of-reach goal or a political slogan, but it is neither. Every other rich country uses the same medical technology, gets the same or better health outcomes, and pays vastly lower sums.

Why the disparity? Health care in America is big business, and in America big business means big lobbying and big campaign contributions, the public interest be damned.

Both parties have therefore ducked the hard work of countering the health care sector's monopoly power. Health care spending is now at $10,000 per person per year, roughly twice or more the total of other high-income countries, or a staggering $3.25 trillion a year.

We should aim to save at least $1 trillion in total annual outlays, roughly $3,000 per person per year, through a series of feasible, fair and reasonable measures to limit monopoly power. Our system would look a lot more like that of the other more successful and less expensive nations.

Here's a 10-point plan Congress should consider.

First, move to capitation for Medicare, Medicaid and the tax-exempt private health insurance plans. Under capitation, hospitals and physician groups receive an annual "global budget" based on their patient population, not reimbursement on a fee-for-service basis.

Second, limit the compensation of hospital CEOs and top managers. The pay of not-for-profit hospital CEOs and top managers, for example, could be capped at $1 million per year.

Third, require Medicare and other public providers to negotiate drug prices on a rational basis, taking account of research and development incentives and the manufacturing costs of the medicines.

Fourth, use emergency power to override patents (such as compulsory licensing of patent-protected drugs) to set maximum prices on drugs for public health emergencies (such as for HIV and hepatitis C).

Fifth, radically simplify regulatory procedures for bringing quality generic drugs to the market, including through importation, by simplifying Food and Drug Administration procedures.

Sixth, facilitate "task shifting" from doctors to lower-cost health workers for routine procedures, especially when new computer applications can support the decision process.

Eight, use part of the annual saving of $1 trillion to expand home visits for community-based health care to combat the epidemics of obesity, opioids, mental illness and others.

Nine, rein in the advertising and other marketing by the pharmaceutical and fast-food industries that has created, alone among the high-income world, a nation of addiction and obesity.

Ten, offer a public plan to meet these conditions to compete with private plans. Medicare for all is one such possibility.

There really no mystery to why America's health industry needs a drastic corrective.

All of these are examples of the vast market power of the health care industry. The sector is designed to squeeze consumers and the government for all they're worth (and sometimes more, driving many into bankruptcy).

The health care sector is a system of monopolies and oligopolies -- that is, there are few producers in the marketplace and few limits on market power. Government shovels out the money in its own programs and via tax breaks for private plans without controls on the market power. And it's getting worse.

Every other high-income country has solved this problem. Most hospitals are government-owned, while most of the rest are not for profit, but without allowing egregious salaries for top management. Drug prices are regulated. Patents are respected, but drug prices are negotiated.

None of this is rocket science. Nor is the United States too dumb to figure out what Canada, the UK, France, the Netherlands, Germany, Japan, Sweden, Norway, Denmark, Finland, Austria, Belgium, Korea and others have solved. The problem is not our intelligence. The problem is our corrupt political system, which caters to the health care lobby, not to the needs of the people.

More here:

Jeffrey Sachs: America can save $1 trillion and get better health care - CNN

John Kasich on Senate Republicans’ health care bill: ‘Are you kidding me?’ – USA TODAY

The Congressional Budget Office estimates twenty-two million fewer people would be insured by 2026 under the GOP's proposed health care plan. USA TODAY

WASHINGTON Ohio Gov. John Kasich ripped Senate Republicans on Tuesday for crafting a health care bill that would cause an estimated 22 million Americans to lose their health insurance.

They think thats great? Thats good public policy? an incredulous Kasich said at anews conferencein Washington on Tuesday. What, are you kidding me?

Kasich was referring toan analysisreleased Monday by the nonpartisan Congressional Budget Office, which estimated that the Senate GOP bill to repeal and replace Obamacare would increase the ranks of the uninsured by 22 million by2026, compared to current law.

Kasich has made his opposition to the GOP bill clear before, but Tuesday he ratcheted up his criticism at a joint news conference with ColoradoDemocratic Gov. John Hickenlooper.

Kasich said congressional Republicans should try getting health care through Medicaid or purchasing insurance with the miserly subsidies the GOP plan offers.

Why dont we have those folks go and live under Medicaid for a while? Kasich said. Why dont we have them go live on their exchange where they can get two, three, four thousanddollars a year to cover their health care exchange costs.

Kasich didnt reserve all his ire for his own party. He also blasted lawmakers of all stripes for acting like a bunch of fifth-graders.

We have a health care civil war going on, he said. Its all about recrimination.

He said Republicans should jettison their current bill and start over, while Democrats should stand and challenge the Republicans to negotiate with them.

Democrats have said they would work with Republicans to fix Obamacare if they stop their efforts to repeal or gut the law.

Read more:

Senate health care bill would lead to 22 million more uninsured, CBO says

Health care bill winners (wealthy) and losers (Medicaid recipients), according to the CBO

Senate GOP leaders face growing opposition to health care bill

Read or Share this story: https://usat.ly/2tSWBae

See more here:

John Kasich on Senate Republicans' health care bill: 'Are you kidding me?' - USA TODAY

After fighting for her daughter’s life, mom fears GOP health care bill – CNN

"We're not deadbeats," said Rebecca Wood, 38, who lives with her husband and daughter in Charlottesville, Virginia.

Wood's daughter, Charlie, was born more than three months early, weighing just one pound and 12 ounces. While she's now 5 years old and doing well, she suffers from complications of her extreme prematurity. She still gets most of her calories through a feeding tube in her stomach.

Wood and her husband have expensive medical bills as a result of these complications.

With the help of Medicaid, Charlie has made great strides. Forty percent of US children are on Medicaid.

After five grueling years, her parents now have confidence that she will realize their dream for her: to grow up to become an independent adult.

But if the Republican health care plans succeed, they worry that dream could die.

"There are these men, just far away from everything, snatching it out from under her," she said.

Arriving early for an appointment with her congressman in May, Rebecca Wood paced the streets of Capitol Hill to calm her nerves.

A few weeks before, on May 4, Virginia Republican Tom Garrett had voted for the American Health Care Act, a plan Wood thinks could endanger her daughter.

As she walked, Wood tried to gather the courage to confront Garrett and a yard sign along her path gave her confidence.

It was a quote from the anthropologist Margaret Mead: "Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has."

Now the stay-at-home mom was ready to tell her story to her congressman.

Wood's blood pressure soared causing doctors at Inova Fairfax Hospital in Falls Church, Virginia, to deliver Charlie at 26 weeks -- 14 weeks early -- to save both of their lives.

After the delivery, Wood went straight to the intensive care unit, her kidneys and liver suffering terribly. Deluded by her disease and the drugs to treat it, she tried to unplug her monitors so she could get to Charlie.

Wood wasn't healthy enough to see her daughter for another two days.

Her husband wheeled her to the neonatal intensive care unit where she looked down into the isolette at her 1-pound, 8-ounce baby and promptly burst into tears.

"I was afraid she wasn't going to survive. It terrified me that this was it," she said.

"I watched you fight and I cheered you on," she would write later in her blog. "On your difficult days, I prayed and begged. Sometimes you would forget to breathe. I gently nudged you as a reminder."

Charlie was discharged after three months in the hospital, though her growth and development lagged behind other babies. She still suffers from delays in speech and fine motor development and is vulnerable to infections, like pneumonia.

Her mother, however, was undaunted.

"I told myself in my head that whatever she could do, we would use whatever her ability is to give her life meaning. If she could hear, then we'd play music for her. If she could only see then we'd take her to look at art and look at the outdoors," she said.

Wood, who had been a social worker, stayed home to focus on Charlie. She took her to doctors' appointments as well as physical, speech, occupational, feeding, and music therapy sessions.

It worked.

By Charlie's first birthday, she could sit up by herself. At 20 months, she took her first steps. Today, she runs around the playground like any child her age. She'll start kindergarten in the fall, a milestone that makes her mother beam.

"She's amazing. She's an incredible kid, but there's a lot of work that went into getting her to where she is," she said.

As she climbed the steps to Garrett's office, Wood said she felt like the character from the iconic movie, "Mr. Smith Goes to Washington," about the reformer who tries to change the system.

Wood set her cell phone on the couch and obtained permission from Garrett's aide to record the conversation.

The very first thing Garrett did was to suggest that Wood was confused about the bill.

"I'm afraid that there's been some hyperbolic mischaracterization of what the reality on the ground is," Garrett said. "It's unfair to you. It's creating fear and anxiety where it need not exist."

Wood assured her congressman she wasn't confused or under anyone's influence. She'd read the GOP bill thoroughly.

She explained that her family has health insurance through her husband's job, but they're still responsible for deductibles, copayments, and other expenses -- which add up to more than $12,000 a year.

Medicaid pays for those extra costs.

Garrett told Wood not to worry, saying "they're not getting rid of Medicaid."

But the House bill, which Garrett voted for, would reduce federal spending on Medicaid by nearly a quarter by 2026 compared to current law, according to a Congressional Budget Office estimate.

Under the GOP Senate plan, which has yet to be put to a vote, some 15 million fewer Americans would be covered by Medicaid in 2026.

Wood is afraid Charlie will be one of them.

Garrett told CNN that care doesn't have to suffer when funding gets slashed.

"The reality is that sometimes you can move money and still get good outcomes," he said.

"So if you had a daughter like Charlie, would you have voted to pass [the GOP plan]?" Wood asked her congressman at their meeting in May.

"Absolutely," he answered.

"Some experts" support the plan, Garrett answered.

"Who?" Wood asked. "Tell me."

"Some have," Garrett answered.

Wood didn't get her answer, but she let it go. Their time was up.

"I know we're banging at each other, but you're doing exactly what you ought to be doing as a mom," Garrett told her.

"I'm sure you're a lovely person. I just disagree with you on this bill," Wood responded.

Before they parted ways, Wood took a photo with her congressman. She says if she looks unhappy in the picture, it's because she was.

"I don't think there are words that express how angry I am that somebody could vote for something that would hurt the people he's supposed to represent," she said.

CNN's Michael Nedelman contributed to this report.

Read more:

After fighting for her daughter's life, mom fears GOP health care bill - CNN

The GOP health-care plan threatens to kill jobs nationwide – Washington Post

Elizabeth Tadesse has cared for elderly residents at the Holly Heights Nursing Center in Denver for eight years now, helping them get dressed and serving them pancakes in bed.

They really rely on us, Tadesse said.

But the health-care bill that senators are discussingthis week would slash funding to Medicaid, which generates 81 percent of her employers revenue and largely covers her wages.

The Better Care Reconciliation Act would reducethe countrys Medicaid spending by $772 billion over the next decade, the nonpartisan Congressional Budget Office projected in a report Monday. That could shut down nursing homes across the country, health-care leaders argue, and trigger widespread layoffs in one of the nation's fastest-growing fields of employment.

Janet Snipes, executive director of Holly Heights, said the proposed cuts would oblige her to reduce her workforce: currently about 170employees who care for 130 residents.

Shrinking the staff, she said, would hamper the center's ability to make life comfortable for the patients an effort that includes bingo and Nintendo Wii, in addition to standard meal and medical services.

We cant take a significant cut and not do staff reduction, she said. And when staff is reduced, care can be compromised.

Tadesse, who quit a job at Walmart to work at Holly Heights, is afraid Medicaid cutsmight reduce her hours.Certified nursing assistants at her facility make about $16 an hour, or $33,000 annually.

If they cut my hours, she said, it would affect me tremendously.

Under theSenate version of the GOP health-care plan, roughly 22 million Americans would lose their health insurance over the next 10 years, the CBO projected. About 15 million would be knocked off Medicaid, the public insurance for the countrys poor.

The largest savings would come from reductions in outlays for Medicaid spending on the program would decline in 2026 by 26 percent in comparison with what CBO projects under current law, the report states.

Though Medicare generally covers older people, Medicaid funds long-term services, including nursing home stays. Nearly two-thirds of Americas 1.4 million nursing home residents rely on Medicaidto cover their care.

Some enter the facilities with little financial resources. Others outlive their savings. Without Medicaidcoverage, doctors say hundreds of thousands would spiral into debt or live without critical services for the disabled.

The public money keepsnursing homes running, Snipes said, since most Americans cant afford the service on their own.

The cost to live at Holly Heights is about $6,000 a month. That includes medical care, food, social functions, laundry, hearing aids, and dental needs.

Mark Parkinson, chief executive of the American Health Care Association and National Center for Assisted Living, which represents about 11,000 nursing homes nationwide, said on a conference call Monday that Medicaid cutsunder the proposed health-care lawwould cost individualnursing homes an average of $100,000 a year overthe first three years.

That would spell disaster for a typical nursing home, which makes about $150,000 annually, he said.

Within a year or two, most buildings in the country would be below their break-even points, Parkinson said. This is not hyperbole.

Roughly 1.7 million people work at nursing homes, mostly in caregiving roles, according to AHCA figures. And health-care employment is rapidly growing especially in areas that serve the elderly. Providing comprehensive, around-the-clock care tends to be labor-intensive.

The Census Bureau estimates that the number of people ages 65 and up in the U.S. will grow from 40 million in 2010 to 72 million by 2030.

Employment of nursing assistants and orderlies, which covers nursing home employees, is expected to keep pace, with a projected growth rate of 17 percent through 2024 or double the growth rate for all occupations, according to the Bureau of Labor Statistics.

Nursing assistants make an average of $26,590 per year.Sara Rosenbaum, founding chair of the Department of Health Policy at George Washington University, calls the growth of such health-care employment a Medicaid workforce.

You destroy the Medicaid program, she said, and you can kiss your nursing homes goodbye.

Layoffs in nursing or health aide roles would disproportionately hurt female and black workers, BLS data suggest. Women fill eighty-seven percent of roles in the sector, while black workers hold 27.3 of the jobs. (The broader workforce is nearly half female and only 11.6 percent black.)

The Hebrew Home at Riverdale, a nonprofit nursing home in the Bronx,is home to roughly900 residents cared for by 800 employees. Theres art therapy, pet therapy comforts provided by fundraising. The bulk of operations, however, is supported by Medicaid.

Ninety percent of residents pay withMedicaid, said Daniel Reingold, chief executive of RiverSpring Health, a senior care organization in New Yorkthat runs Hebrew Home. And entry-level caretakers, who happen to be mostly women, make about $27,000 per year with benefits.

The jobs dont require college degrees and represent a path to stability in the Bronx, where 30 percent of residents live in poverty.

The economic impact that our employment brings to the Bronx is significant, Reingold said. Cuts like this could end up having an impact on wages and benefits.

Read more from the original source:

The GOP health-care plan threatens to kill jobs nationwide - Washington Post

Elizabeth Warren Calls For Democrats To Embrace Single-Payer Health Care – HuffPost

Sen. Elizabeth Warren (D-Mass.) says its time for Democrats to run on single-payer health care across the country.

President Barack Obama tried to move us forward with health care coverage by using a conservative model that came from one of the conservative think tanks that had been advanced by a Republican governor in Massachusetts, Warren, referring to Mitt Romney, said in an interview with The Wall Street Journalpublished Tuesday.

Now its time for the next step. And the next step is single payer, she said.

Warrens comments represent a shift to her position on the U.S. health care system.In March, she said her support for switching to single-payer in which the government handles coverage of health care costs, rather than insurance companies would depend on whether Democrats could find Republican lawmakers willing to help fix the Affordable Care Act passed under Obama.

Republicans, however, have focused on trying to repeal and replace Obamacare. And neither a bill the House passed nor one the Senate is considering both of which would cause more than 20 million people to lose health insurance, according to Congressional Budget Office estimates has any support among Democrats.

Last week, a high-profile effort to establish a single-payer health care system in California stalled amid concerns from both Democratic and Republican lawmakers in the state over how to pay for the estimated $330 billion to $400 billion measure. California Assembly Speaker Anthony Rendon (D) called the measure woefully inadequate.

National Democrats have been reluctant to call for putting single-payer at the top of their party platform. House Minority Leader Nancy Pelosi (D-Calif.), who supports single-payer, rejected the idea earlier this year, saying the issue should be left up to the states because Congress is not ready for it yet.

Republicans say single-payer is unpopular and turns off voters. Matt Gorman, communications director at the National Republican Campaign Committee, goaded Democrats to heed Warrens call for such a system.

The White House is also using the specter of single-payer to persuade Senate Republicans to vote for their partys health care bill.

White House Press Secretary Sean Spicer tweeted that plans by Sen. Bernie Sanders (I-Vt.) to introduce a bill that would create a single-payer system lays out the choice for GOP senators wary of the bill their leaders unveiled last week.

In her Journal interview, Warren called on Democrats to ditch half-measures and commit to progressive policies that they believe in.

Its not like were trying to sell stuff that people dont want. Its not that at all, she said. Its that we havent gotten up there and been as clear about our values as we should be, or as clear and concrete about how were going to get there.

Read the original:

Elizabeth Warren Calls For Democrats To Embrace Single-Payer Health Care - HuffPost

One in five ‘healthy’ adults may carry disease-related genetic mutations – Science Magazine

Two new studies suggest that one in five seemingly healthy people hasDNA mutations that puts him or herat increased risk for genetic disease.

BlackJack3D/iStockPhoto

By Ryan CrossJun. 26, 2017 , 6:15 PM

Some doctors dream of diagnosing diseasesor at least predicting disease riskwith a simple DNA scan. But others have said the practice, which could soon be the foundation of preventative medicine, isnt worth the economic or emotional cost. Now, a new pair of studies puts numbers to the debate, and one is the first ever randomized clinical trial evaluating whole genome sequencing in healthy people. Together, they suggest that sequencing the genomes of otherwise healthy adults can for about one in five people turn up risk markers for rare diseases or genetic mutations associated with cancers.

What that means for those people and any health care system considering genome screening remains uncertain, but some watching for these studies welcomed the results nonetheless. It's terrific that we are studying implementation of this new technology rather than ringing our hands and fretting about it without evidence, says Barbara Biesecker, a social and behavioral researcher at the National Human Genome Research Institute in Bethesda, Maryland.

The first genome screening study looked at 100 healthy adults who initially reported their family history to their own primary care physician. Then half were randomly assigned to undergo an additional full genomic workup, which cost about $5000 each and examined some 5 million subtle DNA sequence changes, known as single-nucleotide variants, across 4600 genessuch genome screening goes far beyond that currently recommended by the American College of Medical Genetics and Genomics (ACMG), which suggests informing people of results forjust 59 genes known or strongly expected to cause disease.

Of the 50 participants whose genomes were sequenced, 11 had alterations in at least one letter of DNA suspected to causeusually rarediseases, researchers report today in The Annals of Internal Medicine. But only two exhibited clear symptoms. One was a patient with extreme sensitivity to the sun. Their DNA revealed a skin condition called variegate porphyria. Now that patient knows they will be much less likely to get bad sunburns or rashes if they avoid the sun and certain medications, says Jason Vassy, a primary care clinician-investigator at Veteran Affairs Boston Healthcare System and lead author of the study.

The team also found that every sequenced patient carried at least one recessive mutation linked to a diseasea single copy of a mutant gene that could cause an illness if two copies are present. That knowledge can be used to make reproductive decisionsa partner may get tested to see if they have a matching mutationand prompt family members to test themselves for carrier status. And in what Vassy calls a slightly more controversial result, the team examined participants chances of developing eight polygenic diseases, conditions that are rarely attributed to a single genetic mutation. Here, they compiled the collective effects of multiple genesup to 70 for type II diabetes and 60 for coronary heart diseaseto predict a patients relative risk of developing the disease.

Just 16% of study volunteers who only reported their family history were referred to genetic counselors or got follow-up laboratory tests. In the genome sequencing group, the number was 34%.

Some researchers have expressed concern that such whole genome screening will skyrocket medical costs or cause undue psychological harm. Aside from the initial cost of sequencing (which was covered by the study), patients who underwent the genomic screen paid an average of $350 additional in healthcare costs over the next 6 months, Vassy and colleagues reported. But contrary to fears of emotional trauma, neither the sequencing group nor the control group showed any changes in anxiety or depression 6 months after the study.

Vassy stresses that their study was small and needs follow-up, but it still impressed Christa Martin, a geneticist at Geisinger Health System, in Danville, Pennsylvania, who worked on the ACMGs recommendations for genome sequencing. I almost feel like the authors undersold themselves, she says. Many of their patients are making health behavioral changes, so they are using the information in a positive way.

The study was extremely well designed and very appropriately run, adds Barbara Koenig, a medical anthropologist who directs the University of CaliforniaSan Francisco Bioethics Program. But she still questions the assumption by many physicians, ethicists, and patient advocates that more information is always beneficial. It is just hard to know how all this information is going to be brought together in our pretty dysfunctional healthcare system.

Another paper published last week on the preprint server bioRxiv, which has not yet undergone peer review, yields similar results. Using whole-exome sequencing, which looks only at the protein-coding regions of the genome, Michael Snyder, director of the Stanford Center for Genomics and Personalized Medicine in Palo Alto, California, and colleagues found that 12 out of 70 healthy adults, or 17%, unknowingly had one or more DNA mutations that increased the risk for genetic diseases for which there are treatment or preventative options.

Both studies suggest that physicians should look at genes beyond the ACMGs 59 top priorities, Snyder says. He argues that whole-genome sequencing should be automatically incorporated into primary care. You may have some super-worriers, but I would argue that the information is still useful for a physician to have. Vassy, however, says that there isnt yet enough evidence to ask insurance companies to reimburse whole genome sequencing of healthy patients.

We like a quick fix and the gene is an important cultural icon right now, so we probably give it more power than it really has, Koenig says. But these are still really early days for these technologies to be useful in the clinic.

Read the original:

One in five 'healthy' adults may carry disease-related genetic mutations - Science Magazine

Court rules hospital can withdraw life support for sick baby Charlie Gard – CNN

Born in August, Charlie Gard has a rare genetic disorder known as mitochondrial DNA depletion syndrome. Caused by a genetic mutation, it leads to weakened muscles and organ dysfunction, among other symptoms, with a poor prognosis for most patients.

Charlie is on life support and has been in the intensive care unit at the Great Ormond Street Hospital for Children in London since October. His doctors wish to take him off life support, but his parents disagree.

"The domestic courts concluded that it would be lawful for the hospital to withdraw life sustaining treatment because it was likely that Charlie would suffer significant harm if his present suffering was prolonged without any realistic prospect of improvement, and the experimental therapy would be of no effective benefit," a press release from the court announcing the decision said.

Charlie's parents appealed to the UK Supreme Court to decide the best interests of their child. After they lost that appeal, the 10-month-old was due to have his life support switched off at the end of the day June 13.

Gard and Yates then filed a request with the European Court of Human Rights, an international court based in Strasbourg, France, to consider the case.

The original ruling to provide life support until June 13 was extended by European Court of Human Rights initially for one week, until June 19. Rather than making a decision then, the court granted a three week-extension, until July 10, to allow for a more informed decision by the court. That extension ended Tuesday with the courts decision.

However, parental rights are not absolute, and in cases in which doctors and parents disagree, the courts may exercise objective judgment in a child's best interest.

In April, a judge tasked with ruling on the impasse between doctors and parents decided in favor of the Great Ormond Street Hospital doctors. In his decision, Justice Francis said life support treatment should end so Charlie could die with dignity.

The boy's parents challenged this ruling in May, yet it was upheld by a Court of Appeal. Three Supreme Court justices later dismissed another challenge from the couple.

Since Charlie's birth, "his condition has deteriorated seriously," the UK Supreme Court stated in a decision June 8; his brain is severely affected, and "he cannot move his arms or legs or breathe unaided."

On this basis, the court ruled that the child's life support should be switched off June 13, but the family appealed to the European court.

Charlie's parents argued that the UK courts gave insufficient weight to their own human rights, and some of Charlie's human rights, in their decision-making, Wilson said.

After the European court's ruling to extend the deadline while judges considered the case further, the Supreme Court told doctors it "would not be unlawful" to continue to provide life support.

After the extension, a Supreme Court hearing was requested by the government and the Great Ormond Street Hospital for Children, which did not know whether the Strasbourg court order was legally binding in the UK, Wilson explained.

"There was also a secondary issue, which was that (Great Ormond Street Hospital's) legal representatives were concerned that at present, doctors did not have sufficient legal clarity about what they can and can't do if Charlie's condition deteriorates," Wilson said. "So this court was also invited to consider whether any UK court, and if so which court, should handle that matter."

In fact, it has never been used to treat this form of mitochondrial DNA depletion syndrome, according to the British ruling, though it has proved beneficial to patients with a different form of the disease.

"He literally has nothing to lose but potentially a healthier, happier life to gain," they said.

Parents are rightly at the "heart" of decisions made about life-sustaining treatment for critically ill children, noted Dominic Wilkinson, director of medical ethics at the Oxford Uehiro Centre.

"Sadly, reluctantly, doctors and judges do sometimes conclude -- and are justified in concluding -- that slim chances of life are not always better than dying." Sometimes, the "best that medicine can do" -- and the most ethical decision -- is to provide comfort and to avoid painful and unhelpful medical treatments, he wrote.

The court said the decision was meticulous, noting that they spoke with Charlie's health care providers, independent experts, experts recommended by the family, and Charlie's parents to inform the ruling. In the end, the press released said they determined, "it was most likely Charlie was being exposed to continued pain, suffering and distress and that undergoing experimental treatment with no prospects of success would offer no benefit, and continue to cause him significant harm."

CNN's Stephanie Halasz, Debra Goldschmidt and Judith Vonberg contributed to this report.

Read the original:

Court rules hospital can withdraw life support for sick baby Charlie Gard - CNN

Mission Health Takes National Leadership Role in Personalized Medicine – Mountain Xpress (blog)

From Mission Health:

Mission Healths Personalized Medicine program focuses on response to drugs in a way that will increase the likelihood that a drug will work effectively while decreasing the likelihood that it will result in a bad side effect for our patients. Personalized medicine testing utilizes the genetic make-up of the individual, or in cancer, the genetic makeup of the patients tumor to predict which drug might be the best match for an individual patient. Mission Health is one of the few community health systems in the nation to offer this vital program for both cancer patients and non-cancer patients.

Important initiatives that are fueling the study and practice of personalized medicine at Mission Health are the 2013 recruitment of nationally known personalized medicine expert Lynn Dressler, PhD to develop and direct the Mission Personalized Medicine Program, the opening of Missions Personalized Medicine Clinic in the Fullerton Genetics Center and a grant from the North Carolina Biotechnology Center (NCBC) to help bring this testing to primary care providers in western North Carolina (the grant helps cover the cost of testing). The NCBC is a private nonprofit organization devoted to building long-term societal and economic benefits to North Carolina by supporting biotechnology research, business, and education across the state.

The NCBC funded pilot study focuses on how testing for drug response can be used effectively in a primary care setting. The pilot study evaluates the barriers that might prevent primary care practices from adopting this testing and how those barriers could be addressed, including opportunities for economic development and job growth. The Mission Personalized Medicine team provides education and training for providers to use and interpret test results.

Dr. Dresslers interest in pursuing solutions to obstacles that currently exist for primary care practices to adopt personalized medicine testing for drug response is the opportunity to enhance care and reduce costs with minimal disruption to the primary care practice current work flow. Patients can only benefit if their providers adopt testing, says Dressler. This study will provide free testing and free education and training to providers, so at least those main barriers are off the table. By giving clinicians and patients an opportunity to try out this testing within a safe environment, it may identify and address other barriers that we have not yet realized.

One year into the NCBC funded study, Dressler and the PM team has successfully recruited 10 clinicians from four primary care practices and tested 41 patients. Recommendations for changes in medication management were suggested in more than one third of patients. The study has already identified additional barriers to be addressed to make this testing more efficient and available to more patients and providers. Future plans for the study include recruitment of several additional practices, with a goal of recruiting approximately 80 total patients from the region. Mission Health plans to conduct other pilot studies to enhance drug management in areas such as behavioral health and supportive care for cancer patients.

Ronald A. Paulus, M.D., President and CEO of Mission Health, who will be speaking at the 13th Annual Personalized Medicine Conference at Harvard Medical School in November declares that personalized medicine offers extraordinary medical possibilities. If we can harness the power of this transformational biomedical technology successfully and we are already beginning to we can improve outcomes for our patients and increase the effectiveness of our dedicated clinicians skillful and compassionate care. At the same time, this technology empowers our patients to be informed, shared decision-makers with their physicians. It is truly an exciting time, he says.

View post:

Mission Health Takes National Leadership Role in Personalized Medicine - Mountain Xpress (blog)

Do YOU have Lynch syndrome? Genetic condition is common cause of killer bowel cancer – Express.co.uk

GETTY

People with Lynch syndrome have an increased risk of bowel cancer and cancer of the womb.

The condition is also known as hereditary non-polyposis colorectal cancer (HNPCC).

The syndrome also increases the risk of the disease reoccurring, but hospitals can screen patients to check if they are at risk.

Bowel Cancer UK said that a lack of systematic testing means that 95 per cent of the 175,000 people with Lynch syndrome are unaware that they have the condition.

GETTY

An estimated 1,100 cases of bowel cancer can be attributed to Lynch syndrome each year, with many of those affected under the age of 50, according to the charity.

The children and siblings of those with Lynch syndrome have a 50 per cent chance of having the condition themselves.

Those with the condition can benefit from regular monitoring and better awareness of symptoms of cancers that they are at increased risk of being diagnosed with.

There are no symptoms of Lynch syndrome, and sometime the first sign a person has Lynch syndrome is when the symptoms of bowel or womb cancer develop.

Getty

1 of 9

Bowel cancer risk factors

This will generally happen a a younger age than people whose cancers are not caused by inherited faulty genes.

Bowel cancer that doesnt run in families usually develops in people over the age of fifth, however people with Lynch syndrome can be affected at the age of 40 or even younger.

Macmillan Cancer Support urged people to be particularly aware of symptoms including

- Blood in stools - Diarrhoea or constipation - Unexplained weight loss - Pain in the tummy

If a person has a suspected cancer believed to be caused by Lynch Syndrome, genetic tests can be done.

Those who do carry the gene might need regular bowel cancer screening from a younger age - such as 25 - and women might need to be screened for womb or ovarian cancer.

GETTY

Professor Nicoline Hoogerbrugge, head of the Radboud university medical centre expert centre on hereditary cancers, Nijmegen, The Netherlands, has said there is an urgent need to find families carrying a mutation for Lynch syndrome in order to decrease mortality from the disease.

The expert has spoken out in favour of raising the age limit for testing.

By implementing appropriate prevention measures, deaths from Lynch syndrome in affected families can be reduced by more than 60 percent over 15 years.

Professor Joris Veltman, Director of the Institute of Genetic Medicine at Newcastle University, Newcastle, United Kingdom, said: It is very important to recognise whether a person suffers from sporadic or familiar cancer, as this identifies family members at risk who can take preventative measures.

For this, genetic tests need to be done in cancer patients."

This study shows that we should extend these genetic tests to older colorectal cancer patients of whom a significant number suffer from familiar cancer.

The rest is here:

Do YOU have Lynch syndrome? Genetic condition is common cause of killer bowel cancer - Express.co.uk

Gene Mutation Linked to Retinitis Pigmentosa in Southwestern US Hispanic Families – Texas Medical Center (press release)

Thirty-six percent of Hispanic families in the U.S. with a common form of retinitis pigmentosa got the disease because they carry a mutation of the arrestin-1 gene, according to a new study from researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.

Retinitis pigmentosa is a group of rare, genetic eye disorders in which the retina of the eye slowly degenerates. The disease causes night blindness and progressive loss of peripheral vision, sometimes leading to complete blindness. According to Stephen P. Daiger, Ph.D., senior author of the study, an estimated 300,000 people in the U.S. suffer from the disease, which gets passed down through families.

In the study published recently in Investigative Ophthalmology & Visual Science, UTHealth researchers found that in a U.S. cohort of 300 families with retinitis pigmentosa, 3 percent exhibited a mutation of the arrestin-1 gene. However, more than 36 percent of Hispanic families from the cohort exhibited the arestin-1 mutation and they all came from areas in the Southwestern U.S., such as Texas, Arizona and Southern California.

When I started studying retinitis pigmentosa in 1985, we set out to find the one gene that causes the disease. Thirty-three years later, weve found that more than 70 genes are linked to retinitis pigmentosa, said Daiger, a professor in the Human Genetics Center and holder of the Thomas Stull Matney, Ph.D. Professorship in Environmental and Genetic Sciences at UTHealth School of Public Health.

Some of the genes that cause retinitis pigmentosa are recessive, which means two mutations are required, and some are dominant, which means you only need one mutation. Arrestin-1 piqued Daigers interest because that particular mutation is dominant while all previously found mutations in the gene are recessive. This unexpected finding shows that even a single mutation in the gene is sufficient to cause the disease.

Daiger and his team have identified the genetic cause of retinitis pigmentosa for 75 percent of families in their cohort. Possible treatments for some forms of retinitis pigmentosa are being tested but are still limited. However, the speed at which companies are developing gene therapies and small molecule therapies gives reason to hope, he said. Daiger and his collaborators have begun to connect some of the patients in the retinitis pigmentosa cohort to clinical trials that treat specific genes.

I want our cohort families to know that even if there is not an immediate cure for their specific gene mutation, at this rate it wont be long until a therapy becomes available, said Daiger, who also holds the Mary Farish Johnston Distinguished Chair in Ophthalmology at McGovern Medical School at UTHealth.

UTHealth coauthors include Lori S. Sullivan, Ph.D.; Sara J. Browne, Ph.D.; Elizabeth L. Cadena; Richard S. Ruiz, M.D., and Hope Northrup, M.D. Additional co-authors are from Nationwide Childrens Hospital; Kellogg Eye Center at the University of Michigan; Retina Foundation of the Southwest; Casey Eye Institute at Oregon Health and Science University; Vanderbilt University and the Department of Molecular and Human Genetics at Baylor College of Medicine.

Support for the study, titled A novel dominant mutation in SAG, the arrestin-1 gene, is a common cause of retinitis pigmentosa in Hispanic families in the Southwestern United States, was provided by the William Stamps Farish Fund and the Hermann Eye Fund.

Additional support was provided by the National Institutes of Health (EY007142, EY009076, EY011500, EY010572 and K08-EY026650), a Wynn-Gund TRAP Award, the Foundation Fighting Blindness, the Max and Minnie Voelker Foundation and a grant to the Casey Eye Institute from Research to Prevent Blindness.

See the rest here:

Gene Mutation Linked to Retinitis Pigmentosa in Southwestern US Hispanic Families - Texas Medical Center (press release)

Simple, affordable tests can prevent genetic disorders – Khaleej Times

Premarital tests are so important, but what's most important is for couples to understand the consequences of their union

Over 400 genetic disorders are present among the UAE's populace, however, its continued spread can be prevented by simple and affordable tests, some costing as little as Dh30, according to local health experts.

Dr Ebtehaj Al Anizi, Obstetrics and Gynaecology specialist, told Khaleej Times that genetic disorder prevention tests are crucial, especially when it comes to consanguineous marriages. However, she stressed that not all couples take the results, nor the doctor's advice seriously, leading to devastating consequences for their offspring's health.

"As marriage between relatives is common in the region, so is the risk of genetic diseases. A lot of high risk couples do no listen to us when advised not to go ahead with the marriage," Dr Al Anizi said.

Dr Al Anizi said the most common genetic disorders in the UAE include thalassemia, sickle cell anaemia, G6PD deficiency, cystic fibrosis and haemophilia. Raising awareness about the suffering of future children who could inherit the disease is vital. "If both parents are thalassemia minor, then their offspring, who will have thalassemia major, will suffer greatly. The child will have chronic anaemia, and their lives will depend on frequent blood transfusions."

Dr Al Anizi said this is when doctors often advise couples to not get married. "These kids suffer a lot: they have anaemia, fatigue, the structure of their faces and bones change, they have enlargement in the belly, and unfortunately, often die before they reach 10."

She said sick cell disease can also be prevented in the next generation, by testing both parties. "If the child inherits this disease, it really is a crisis for the entire family."

Premarital tests important

Dr Al Anizi stressed that common health problems, including a severe drop in oxygen levels, body and chest pain, as well as fatigue, will arise. "Children are often admitted to the emergency department and need heavy medication and painkillers. The pain is intolerable.

"Premarital tests are so important, but what's most important is for couples to understand the consequences of their union."

Dr Mariam Mater, founder and chairperson of the UAE Genetic Diseases Association (UAE GDA), said prevention tests are accessible in the UAE and are cost effective in the long run. "The cost of genetic screening of thalassemia is Dh120, and the cost of treating a patient is Dh35,000 per annum."

She stressed that the risk of neural tube defects, which are also common in the UAE, can also be prevented by a course of folic acid, which costs approximately Dh30, whereas treating a neural tube defects case costs a whopping Dh2.7million.

"Prevention is the key in reducing the impact of genetic disorders, socially and economically, and is a long-term sustainable solution, especially in a country like ours where close to 60 per cent of the population is under 30 years of age."

Genetric engineering helps

Genetic engineering could help couples in the UAE conceive healthy children. Dr Rashmi Mathai, Internal Medicine specialist, Universal Hospital, said a recent research in the US revealed that genetic engineering may help curb the manifestation of genetic disorders in the next generation, which will be a huge relief for couples in the UAE, if made available in the country.

"A patient carrying a mutation that carries a genetic disease, such as cystic fibrosis, may simultaneously carry a mutation in another gene that buffers the effect of the harmful gene. This buffer gene unravels a whole new treatment modality for those carrying genetic diseases.

"This type of genetic engineering will certainly help a lot of couples if it comes to the UAE," Dr Mathai said.

However, Dr Mathai pointed out that couples in the UAE cannot depend on waiting to see what the future of genetic engineering unravels, and must thus opt for what is already available, to help prevent the increasing genetic diseases statistics. "The closer the blood relation between the spouses, the higher the chance the children will carry the disease. Public awareness and premarital counselling are the most important aspects, because it could help save lives."

jasmine@khaleejtimes.com

MORE FROM News

With over 200 nationalities residing in the UAE, the country is a... READ MORE

Children also breathe faster, hence are more susceptible to illnesses ... READ MORE

With the three-week programme, students and parents managed to create ... READ MORE

Among other side effects of black henna are blisters, redness, cuts,... READ MORE

MORE FROM Khaleej Times

The police have detained several friends and acquaintances of the... READ MORE

The number of companies and agencies reportedly affected by the... READ MORE

The citizens of Switzerland and the United Kingdom are also part of... READ MORE

The amendments also permit no more than 50 per cent glass tinting for ... READ MORE

Continue reading here:

Simple, affordable tests can prevent genetic disorders - Khaleej Times

Genetic engineering tool generates antioxidant-rich purple rice – Phys.Org

June 27, 2017 A photograph of purple endosperm rice. Credit: Qinlong Zhu of the South China Agricultural University

Researchers in China have developed a genetic engineering approach capable of delivering many genes at once and used it to make rice endospermseed tissue that provides nutrients to the developing plant embryoproduce high levels of antioxidant-boosting pigments called anthocyanins. The resulting purple endosperm rice holds potential for decreasing the risk of certain cancers, cardiovascular disease, diabetes, and other chronic disorders. The work appears June 27th in the journal Molecular Plant.

"We have developed a highly efficient, easy-to-use transgene stacking system called TransGene Stacking II that enables the assembly of a large number of genes in single vectors for plant transformation," says senior study author Yao-Guang Liu of the South China Agricultural University. "We envisage that this vector system will have many potential applications in this era of synthetic biology and metabolic engineering."

To date, genetic engineering approaches have been used to develop rice enriched in beta-carotene and folate, but not anthocyanins. Although these health-promoting compounds are naturally abundant in some black and red rice varieties, they are absent in polished rice grains because the husk, bran, and germ have been removed, leaving only the endosperm.

Previous attempts to engineer anthocyanin production in rice have failed because the underlying biosynthesis pathway is highly complex, and it has been difficult to efficiently transfer many genes into plants.

To address this challenge, Liu and his colleagues first set out to identify the genes required to engineer anthocyanin production in the rice endosperm. To do so, they analyzed sequences of anthocyanin pathway genes in different rice varieties and pinpointed the defective genes in japonica and indica subspecies that do not produce anthocyanins.

Based on this analysis, they developed a transgene stacking strategy for expressing eight anthocyanin pathway genes specifically in the endosperm of the japonica and indica rice varieties. The resulting purple endosperm rice had high anthocyanin levels and antioxidant activity in the endosperm. "This is the first demonstration of engineering such a complex metabolic pathway in plants," Liu says.

In the future, this transgene stacking vector system could be used to develop plant bioreactors for the production of many other important nutrients and medicinal ingredients. For their own part, the researchers plan to evaluate the safety of purple endosperm rice as biofortified food, and they will also try to engineer the biosynthesis of anthocyanins in other crops to produce more purple endosperm cereals.

"Our research provides a high-efficiency vector system for stacking multiple genes for synthetic biology and makes it potentially feasible for engineering complex biosynthesis pathways in the endosperm of rice and other crop plants such as maize, wheat, and barley," Liu says.

Explore further: The origin and spread of 'Emperor's rice'

More information: Molecular Plant, Zhu et al.: "Development of ''Purple Endosperm Rice'' by Engineering Anthocyanin Biosynthesis in the Endosperm with a High-Efficiency Transgene Stacking System" http://www.cell.com/molecular-plant/abstract/S1674-2052(17)30140-5 , DOI: 10.1016/j.molp.2017.05.008

Journal reference: Molecular Plant

Provided by: Cell Press

Black rice has a rich cultural history; called "Forbidden" or "Emperor's" rice, it was reserved for the Emperor in ancient China and used as a tribute food. In the time since, it remained popular in certain regions of China ...

We've all heard examples of animal altruism: Dogs caring for orphaned kittens, chimps sharing food or dolphins nudging injured mates to the surface. Now, a study led by the University of Colorado Boulder suggests some plants ...

(Phys.org)Hybrids of many plant and animal species and subspecies are sterile, and a group of researchers in China have now identified the genes that operate to make crossbred rice sterile.

The origins of rice have been cast in a new light by research publishing in the open-access journal PLoS Genetics on June 9, 2011. By reconciling two theories, the authors show that the domestication of rice occurred at least ...

Anthocyanins, plant pigments known for their health-promoting properties, are in demand for medicinal and industrial uses. Anthocyanins have become sought-after natural products, but the small number of plants that naturally ...

Anthocyanins, pigments that give plants their red, blue, or purple hues, are not typically produced in citrus fruits grown under tropical or subtropical conditions. Now, scientists have genetically engineered a lime that ...

When insects skip the light fandango their romantic foreplay often involves some pretty crazy things like hypnotic dance moves and flashy colors. In some species it ends with a complex ejaculate package that does more than ...

A study of yeast reveals new mechanism that allows cells to adapt to environmental changes more rapidly by accelerating genetic changes around genes that boost fitness, publishing 27 June in the open access journal PLOS Biology, ...

In the fight against the viruses that invade everyday life, seeing and understanding the battleground is essential. Scientists at the Morgridge Institute for Research have, for the first time, imaged molecular structures ...

Researchers from the University of Zurich and the University Hospital Zurich have discovered the protein that enables natural embryonic stem cells to form all body cells. In the case of embryonic stem cells maintained in ...

For us humans, it goes without saying that we reward others as an indication of the gratitude we feel towards them. Scientists from the Max Planck Institutes for Evolutionary Anthropology and for Mathematics in the Sciences ...

Researchers in China have developed a genetic engineering approach capable of delivering many genes at once and used it to make rice endospermseed tissue that provides nutrients to the developing plant embryoproduce ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original:

Genetic engineering tool generates antioxidant-rich purple rice - Phys.Org

HIV fix: Can gene editing work alongside the virus to provide a cure? – Genetic Literacy Project

Gene therapy and management of human immunodeficiency virus (HIV) infection haveeventful histories going back several decades. Both are saving lives today and both are innovating in ways that will lead soon to a convergence. In the years to come, gene therapy and other therapeutic genetic engineering modalities will be used against HIV. The conventional strategy for gene therapy is addition of new genes to a patients genome. ButHIV requires new approaches inspired by anti viral tricks from nature if we hope to reduce the damage being done to third-world nations by the virus.

The currentstrategy in gene therapy is based onlimiting,replacing or supplementing defective genes. This is a workable approach for recessive genetic diseases. However, right around the corner is the option of deleting genes, and subsequently line-item editing of genes that are too large to fit inside AAV, a virus that gene therapists commonly use as a carrier for genetic payloads. Both gene deletion and line-item editing of larger genes can be achieved using CRISPR genome editing carried inside an AAV. But ironically, the HIV itself could work better as a carrier for anti-HIV gene therapy. At the same time, modulating the immune response by suppressing gene activity without deleting the relevant gene is showing promise in laboratory studies. This approach utilizes a non-CRISPR genetic engineering tool, RNA interference (RNAi).

As gene therapy has evolved, scientists have anticipated its eventual use as an HIV treatment. Butwhy consider gene therapy against an infectious disease? For inherited enzyme deficiencies like cystic fibrosis and Tay-Sachs disease, and for cancer, the potential for gene therapy seems fairly intuitive. But a well-known feature of infectious diseases is their ability to generate an immune response. When exposed to a foreign agent, our bodies launch a T-cell and antibody response. For the vast majority of diseases that impacted human mortality at the dawn of the 20th century, medical researchers were able to boost the immune response with vaccines. Polio, diphtheria, measles all the major infectious killers that plagued our ancestors are prevented today. But a minority of microbial nemeses have evolved particularly devious tricks. Mycobacterium tuberculosis is one of them; so is the Plasmodium parasite that causes malaria. They hide in human tissues, so vaccine development has been particularly challenging.

HIV has multiple ways to evade both the sensors and armaments of the human immune system. Once it enters human cells as a retrovirus, it normally embeds itself into the human genome through a reversal of the whats called the genetic dogma. The latter refers to the passage of genetic information only in one direction, from DNA to RNA to proteins. In violation of the genetic dogma, an enzyme called reverse transcriptase enables HIV and other retroviruses to create DNA from RNA sequences that are carried in the viral genome. This makes removal of HIV analogous to the task of getting toothpaste back into the tube; theoretically, its possible, but snazzy techniques are required.

In gene therapy 1.0, only new genes can be added, so that cannot help with HIV. But the advent of CRISPR in 2012 has addedthe prospect of using gene therapy to delete genes, although one would still need an innovative tactic for identifying those sequences and weeding them out. RNAi is another genetic engineering modality, one that Caltech HIV researcher andNobel laureate David Baltimore believes entails particular potential. The target for RNAi is messenger RNA (mRNA), the sub-type of RNA that carries the genetic sequence transcribed from a DNA gene. In RNAi, special molecules are slipped into cells to suppress activity of mRNA strands.

Research published recently in the online journal PLOS ONE implies a possible new strategy. The study suggests that a strain of HIV called HIV-1 works by hijacking species-specific adaptations that nature has evolved. This makes the virus infectious to some ape species, but not others. CRISPR-based gene therapy we might call it gene therapy 2.0, or RNAi, potentially can incorporate the species-dependent mechanisms employed by HIV itself. This means either eliminating HIV from a patients genome, or rendering the virus neutral by blocking mRNA that is made from viral instructions.

The challenge is figuring out whichgenes should be targeted with this method. The answer could come from a minority of humans with a genetic deficiency that makes them resist HIV infection. To cause disease, HIV requires a certain protein on the surface of the immune systems T-cells. People who cannot make that protein because the copy of the gene from both mother and father are defective are protected from HIV. Those who have one normal gene copy and one defective copy are partially protected. Thus, use of RNAi against the mRNA made from this gene should be protective as well.

These strategies can lead to a sea change in the fight against the HIV pandemic, particularly in developing countries. In developed countries, when diagnosed at an early stage, HIV is not a death sentence, but staying alive requires constant vigilance and treatment. Similar to diabetes, survival depends on monitoring a patients health, adjusting drug treatment accordingly, and managing complications aggressively. Gold standard treatment consists of drug combination therapy, which means using multiple classes of medications, each that attacks the virus through a different mechanism.

Earlier, we mentioned the enzyme reverse transcriptase and how it enables HIV to incorporate its genes into the human genome by causing DNA sequences to be created using RNA sequences. The enzyme is encoded by the virus own genes. Inside the virus, those viral genes exist as RNA sequences, not DNA sequences, and they include the genetic sequence that creates the enzyme. But in the 1990s, researchers began using drugs that inhibit reverse transcriptase and showed that they can slow the onset of acquired immunodeficiency syndrome (AIDS) in HIV-infected patients. Today, there several reverse transcriptase inhibitor drugs, divided into two classes that work differently.

Physicians also have another drug class at their disposal, protease inhibitors, which interfere with another process thats vital to HIVs ability to reproduce itself. When patients are given both reverse transcriptase inhibitors (often more than one type) plus protease inhibitors, survival can continue for many years, and improves still more when an additional class of drugs is added. This is the current paradigm, but, like diabetes therapy, it keeps patients alive without curing them.

Combination therapy is extremely expensive and requires excellent patient compliance, and also societal support. All of these factors make it particularly challenging in developing countries, where HIV infection therefore has a much worse prognosis than it has here in North America, or in Europe.

The prospect of a high-tech approach like gene therapy solving a major public health issue like HIV may sound far-fetched. After all, high-tech solutions generally take hold in developed countries first. The same pattern is likely with HIV. Developed, rich countries will have the treatment first. But if it does work and eliminates the virus, it wont require the kind of followup and constant vigilance thats central to standard combination drug therapy.

David Warmflash is an astrobiologist, physician and science writer. Follow @CosmicEvolution to read what he is saying on Twitter.

Go here to see the original:

HIV fix: Can gene editing work alongside the virus to provide a cure? - Genetic Literacy Project

Gene Therapy: A New Twist on an Old Helix – Genetic Engineering & Biotechnology News

Many Helpers Make Light Work

Targeting cancer cells that have spread to several organs of the body is difficult. Targeted radiation therapy or chemotherapy tends to destroy not only the cancer cells but also normal cells. Turning to gene therapy to selectively deliver therapeutic genes into these cancer cells on a larger scale and eliminating them in one fell swoop is the ultimate goal of Tocagen.

Using two products, Toca 511 and Toca FC, the company plans on developing an effective combination therapy that could hit the cancer hard. Toca 511 is an injectable retroviral replicating vector (RRV) that provides the genetic material to encode a prodrug activator enzyme, cytosine deaminase (CD), which is derived from yeast and has no human counterpart. It is selectively delivered to only cancer cells, thus producing the CD protein in each cell.

Part two of this therapy involves a pill called Toca FC, which contains 5-fluorocytosine (5-FC) that converts to the anticancer agent 5-FU in the presence of CD protein. Toca FC kills not only the cancer cells, but also the myeloid-derived suppressor cells (MDSCs), which suppress the immune system, and tumor-associated macrophages (TAMs).

Harry Gruber, M.D., cofounder and former CEO of Tocagen, talks about the use of gamma-retroviruses: The advantage of using a gamma-retrovirus (as opposed to the lentivirus) is that it cannot enter the nucleus on its own. This makes it selective to dividing cells only, and since cancer cells are rapidly dividing, [gamma-retroviruses] help in spreading the virus and its genetic information. They live in defective cells that lack an innate immunity, and due to this selectivity, they are designed to be universally geared toward only cancer cells.

Dr. Gruber also mentioned that Toca 511/FC received the FDAs Breakthrough therapy designation, which expedites drug development.

The field of gene therapy has come a long way since its inception. Early failures and setbacks forced researchers back to the drawing board to figure out how viral vectors could be accepted by the human body, which ordinarily rejects foreign particles. Researchers also had to learn how such vectors could reach specific targets and deliver foreign DNA that could be integrated into the genome. This dance between therapy and the innate immune system is getting more complex, but is also showing its true beauty within the complexity.

Originally posted here:

Gene Therapy: A New Twist on an Old Helix - Genetic Engineering & Biotechnology News

More good news for Bluebird Bio with CALD gene therapy – pharmaphorum

Bluebird Bio haspresented encouraging data from its gene therapy treatment for the rare condition, cerebral adrenoleukodystrophy (CALD).

The company is competing with other pioneering firms to develop transformative gene therapies for severe genetic diseases, as well as T cell-based immunotherapies for cancer.

It has had a run of good news recently, including encouraging early stage results from its multiple myeloma candidate bb2121 at ASCO.

But gene therapy Lenti-D is one of its two most advanced candidates, and has just produced encouraging topline interim data from its Phase 2/3 Starbeam Study (ALD-102).

Lenti-D is being studied in boys under 18 years old with CALD. The data shows that two years after receiving the gene therapy, 15 out of the 17 boys on the trial show are free of major functional disabilities (MFDs), the primary endpoint of the trial.

Also known as Lorenzos Oil disease, adrenoleukodystrophy (ALD) is estimated to affect one in every 21,000 male births worldwide. Cerebral adrenoleukodystrophy (CALD), is a potentially fatal form of ALD that affects the nervous system of boys, and involves a breakdown of the protective sheath of the nerve cells in the brain that are responsible for thinking and muscle control.

The current standard treatment for CALD is allogeneic hematopoietic stem cell transplant (HSCT), but complications including graft failure, graft versus host disease (GVHD) and opportunistic infections can be fatal.

The Lenti-D therapy involves genetically modifying a patients own stem cells to contain functional copies of the ABCD1 gene. This restores the production of the missing ALDP protein, which helps to break down the very long chain fatty acids (VLCFAs) which cause the neurodegeneration.

David Davidson

The hope that Lenti-D may benefit boys facing such a devastating disease inspires all of us at bluebird, said David Davidson, M.D., chief medical officer, Bluebird Bio.

Having this proportion of the initial cohort of patients meet the primary endpoint is truly gratifying, bringing us one step closer to our goal of making Lenti-D available for patients with CALD. The two patients who did not meet the primary endpoint underscore the devastating nature of CALD, the importance of early diagnosis through newborn screening, and the challenges of the current standard of care with allogeneic hematopoietic stem cell transplant (HSCT).

The company commented on the condition of the two patients who hadnt responded, including Patient 2016, whose disease progressed before he could receive the new treatment. He subsequently died from complications of the allogeneic transplantation, underlining the problems with current treatment.

Bluebird said the Starbeam Study showed the safety profile of Lenti-D was consistent with myeloablative conditioning, with no patients treated experiencing graft versus host disease (GvHD), graft rejection or clonal dominance.

The Starbeam study had been expanded to treat eight additional patients at sites in Europe and the US, and the study is currently enrolling the additional patients. It says this expansion is intended to enable the first manufacture of Lenti-D in Europe, expand treatment to Europe and to bolster its overall clinical data package ahead of filing.

The company has also just announced encouraging data from its other lead candidate, LentiGlobin.Its phase 3 Northstar-2 studyin transfusion-dependent -thalassemia (TDT) and non- genotypes shows that trial participants are free from transfusions, three and a half years after receiving treatment.

The firm, based in Cambridge, Mass, has also just announced announced a public offering of $350 million of common stock to help fund its R&D plans.

More here:

More good news for Bluebird Bio with CALD gene therapy - pharmaphorum

Noted Futurist Looks Back: How Espionage, Arms Deals and Recent … – PR Newswire (press release)

Former defense contractor-turned-author and futurist David Treichler -- writing as dhtreichler -- sheds startling light on the twists and turns of the "Armaments Bazaar" process in his new book, and portrays weapons sales to contentious Middle East countries as sometimes problematic -- and even dangerous.

Drawn from Treichler's real-world experiences in the Middle East, it offers insights into espionage, intelligence failures and the cat-and-mouse games played in suppressing the peoples of the region. He details transactions with often life-and-death consequences for both the citizens of these nations -- and their sovereign neighbors.

The fiction-based-on-fact book, called simply, Rik's, is available at http://amzn.to/2q9iDWV. In addition, you can view a video book trailer at https://youtu.be/8u5ZtDX-ToY.

As time has proven, the sale of weapons and intelligence systems can prove pivotal to countries like Iraq, Iran, Turkey and, currently, Syria, under strongman Bashar al-Assad.

Treichler admits he -- like his lead character in the novel -- sometimes had misgivings about the end use of the weapons he sold. But, in the final analysis, following U.S. policy to maintain arms parity in the volatile region was the only option, he says.

The book is about an American State Department official whose day job is to help U.S. companies reach trade agreements.

By night, however, he gathers intelligence and arranges the sale of military hardware to maintain the balance of power in the region. In the novel, he is also the CIA station chief who has fallen in love with a broadcast journalist.

"Five stars for Rik's," writes the Midwest Book Review. "It speaks eloquently about such vital issues as patriotism, comradeship, and the lengths to which love will go. This gritty read will ring true with any follower of America's foreign interventions."

It is also available online at dhtreichler.com.

Media Contact: David Treichler, Author dtreichler1@verizon.net (817) 909-2128 (cell phone)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/noted-futurist-looks-back-how-espionage-arms-deals-and-recent-history-sowed-the-seeds-of-todays-terrorism-300479353.html

SOURCE dhtreichler

http://dhtreichler.com/

See the article here:

Noted Futurist Looks Back: How Espionage, Arms Deals and Recent ... - PR Newswire (press release)